Dong, Jie <br/><br/>
Interleukin-6 and mevastatin regulate plasminogen activator inhibitor-1 through CCAAT/enhancer-binding protein-delta.  [electronic resource] 

 -  Arteriosclerosis, thrombosis, and vascular biology  May 2005 
 - 1078-84 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1524-4636 
<br/><br/><label>Standard No.: </label>10.1161/01.ATV.0000159701.24372.49  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Atherosclerosis--drug therapy<br/>CCAAT-Enhancer-Binding Protein-delta--genetics<br/>Carcinoma, Hepatocellular<br/>Cell Line, Tumor<br/>Cell Nucleus--physiology<br/>Chromosome Mapping<br/>Gene Expression--drug effects<br/>Hepatocytes--drug effects<br/>Humans<br/>Hydroxymethylglutaryl-CoA Reductase Inhibitors--pharmacology<br/>Interleukin-6--genetics<br/>Liver Neoplasms<br/>Lovastatin--analogs & derivatives<br/>Mice<br/>Mice, Inbred ICR<br/>Mutagenesis, Site-Directed<br/>Plasminogen Activator Inhibitor 1--genetics<br/>Promoter Regions, Genetic<br/>RNA, Messenger--metabolism<br/>Response Elements<br/>Thrombosis--physiopathology<br/>Transfection